Guralnik J, Bandeen-Roche K, Bhasin S A R, Eremenco S, Landi F, Muscedere J, Perera S, Reginster J-Y, Woodhouse L, Vellas B
Jack Guralnik, University of Maryland School of Medicine, Baltimore, MD, USA,
J Frailty Aging. 2020;9(1):9-13. doi: 10.14283/jfa.2019.33.
For clinical studies of sarcopenia and frailty, clinically meaningful outcome measures are needed to monitor disease progression, evaluate efficacy of interventions, and plan clinical trials. Physical performance measures including measures of gait speed and other aspects of mobility and strength have been used in many studies, although a definition of clinically meaningful change in performance has remained unclear. The International Conference on Frailty and Sarcopenia Research Task Force (ICFSR-TF), a group of academic and industry scientists investigating frailty and sarcopenia, met in Miami Beach, Florida, USA in February 2019 to explore approaches for establishing clinical meaningfulness in a manner aligned with regulatory authorities. They concluded that clinical meaningful change is contextually dependent, and that both anchor- based and distribution-based methods of quantifying physical function are informative and should be evaluated relative to patient-reported outcomes. In addition, they identified additional research needed to enable setting criteria for clinical meaningful change in trials.
对于肌肉减少症和衰弱的临床研究,需要有具有临床意义的结局指标来监测疾病进展、评估干预措施的疗效以及规划临床试验。许多研究都采用了包括步态速度测量以及其他运动能力和力量方面的身体性能测量指标,尽管对于表现上具有临床意义的变化的定义仍不明确。国际衰弱和肌肉减少症研究任务组(ICFSR-TF)是一组研究衰弱和肌肉减少症的学术和行业科学家,于2019年2月在美国佛罗里达州迈阿密海滩召开会议,探讨以符合监管机构要求的方式确立临床意义的方法。他们得出结论,临床意义上的变化取决于具体情况,基于锚定和基于分布的量化身体功能的方法都能提供有用信息,并且应该相对于患者报告的结局进行评估。此外,他们确定了还需要开展更多研究,以便能够为试验中具有临床意义的变化设定标准。